Rezolute (RZLT) Reiterated at Neutral by Cantor Fitzgerald After FDA Meeting

March 25, 2026 7:02 AM

Cantor Fitzgerald analyst Pete Stavropoulos reiterated a Neutral rating on Rezolute (NASDAQ: RZLT).The analyst commented, "We caught up with RZLT ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found